SELECTED QUARTERLY INFORMATION - UNAUDITED

12 Months Ended

Dec. 31, 2012

Selected Quarterly Financial Information [Abstract]

SELECTED QUARTERLY INFORMATION - UNAUDITED

SELECTED QUARTERLY INFORMATION - UNAUDITED

	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
	(In thousands, except per share data)
Total revenue, net:
2012	$	196,185	$	210,170	$	210,084	$	214,432
2011	181,041		193,329		202,185		203,523
Gross margin:
2012	$	121,510	$	131,896	$	130,536	$	132,502
2011	116,120		120,491		123,534		120,783
Net income (loss):
2012	$	6,693	$	8,514	$	13,211	$	12,786
2011	11,487		699		11,243		4,560
Basic net income (loss) per common share(1)(2):
2012	$	0.24	$	0.30	$	0.46	$	0.46
2011	0.39		0.02		0.39		0.16
Diluted net income (loss) per common share(1)(2):
2012	$	0.23	$	0.30	$	0.46	$	0.46
2011	0.38		0.02		0.39		0.16

(1) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing shares of its common stock during the year.

(2) Certain of the Company’s unvested restricted share units contain rights to receive nonforfeitable dividends, and thus, are participating securities requiring the two-class method of computing earnings per share. The participating securities had an insignificant impact on the calculation of earnings per share (impacts the rounding by less than $0.01 per share) on all of the periods presented; therefore, the Company does not present the full calculation.

Interest expense for the fourth quarter of 2012 includes an out-of-period adjustment to record a decrease to interest expense of $3.3 million related to not capitalizing interest cost on certain construction in progress balances, of which $1.5 million related to the first three quarters of 2012, $1.4 million for the full year 2011 and $0.4 million for the last quarter of 2010. The Company believes that both the actual interest expense errors and the correction of those errors out of period in the fourth quarter of 2012 are not material.

The Company incurred incremental costs related to the implementation of its global enterprise resource planning system in the first, second, third, and fourth quarters of 2012 of $3.7 million, $3.6 million, $4.8 million and $4.3 million, respectively.

The Company incurred costs related to the remediation of an FDA warning letter and the related underutilization at its Plainsboro, New Jersey manufacturing facility of $1.6 million, $1.8 million, $3.8 million and $0.7 million in the first, second, third and fourth quarters of 2012, respectively.